NCT04623216 - Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 14, 2021

Primary Completion Date

August 22, 2024

Study Completion Date

August 22, 2024

Conditions

Acute Myeloid Leukemia

Interventions

BIOLOGICAL

Sabatolimab

Sabatolimab is a solution in vial for IV infusion

DRUG

Azacitidine

Azacitidine comes in Vial for IV infusion or subcutaneous administration

Trial Locations (9)

Novartis Investigative Site, Marseille

Novartis Investigative Site, Hamburg

Novartis Investigative Site, Bergamo

Novartis Investigative Site, Brescia

Novartis Investigative Site, Bologna

Novartis Investigative Site, Münster

Novartis Investigative Site, Freiburg im Breisgau

Novartis Investigative Site, Roma

Novartis Investigative Site, Barcelona